News archive

Professor Eleni Aklillu, GH-Pharma research group leader at the Department of Global Public Health, is leading the coordination of the EU MAV+ project in Rwanda. Sweden is part of the Team Europe initiative with a total budget of €10 million, managed by Sida.

Every year in October, when the recipients of the Nobel Prizes are announced, the Nobel Prize Museum organizes events and meetings in collaboration with, among others, Karolinska Institutet. This year Professor Tobias Alfvén from the Department of Global Public Health teamed up with Secretary General of UNICEF Sweden Pernilla Baralt for a seminar about vaccination.

The very idea of a vaccine is to prevent a disease from occurring. By exposing the body to a small part of an infectious agent that causes a disease, but doing so in a killed or weakened form, the body develops a defense against the disease. In a sense, vaccines can be argued to be the ultimate form of preparedness, as they prevent the disease from occurring in the first place, or at least mitigate it.

Vaccination coverage for COVID-19 is high in both people with and without mental illness, according to a large multinational study led by researchers at Karolinska Institutet and published in Nature Communications. However, Swedish registry data revealed that individuals with unmedicated mental illness have lower vaccination levels.

The International Vaccine Institute (IVI) will be teaming up with specialists from KI again this year for a vaccinology course aimed at healthcare professionals and researchers from around the world. The course also now forms part of doctoral education at KI.

Children who have undergone treatment for cancer often lose the protection against infection provided by previous vaccinations. Anna Nilsson is studying how cancer therapies affect the immune system in order to improve vaccination guidelines for these children. Meet one of the new professors of Karolinska Institutet who will participate in this year's installation ceremony at Aula Medica on 3 October.

Girls with mental illness or neurodevelopmental conditions are less likely than their peers to be vaccinated with the HPV vaccine that protects against future cervical cancer. This is according to a new registry study from Karolinska Institutet published in The Lancet Public Health.

Researchers at Karolinska Institutet, in collaboration with JLP Health and others, have identified how the tick-borne Crimean-Congo haemorrhagic fever virus enters our cells. The results are published in Nature Microbiology and are an important step in the development of drugs against the deadly disease.

Catherine J. Wu, of the Dana-Farber Cancer Institute in Boston, USA, is a pioneer in research that may result in the development of personalised vaccines to treat cancer. She is now awarded the Sjöberg Prize, worth one million US dollars, for her work. Catherine J. Wu will give a lecture in Aula Medica at KI on April 12 in connection with the Karolinska CCC Day.

No increased risks for babies, and for some serious neonatal complications lower risks. This is the result of the largest study to date on the safety of newborn babies whose mothers were vaccinated against COVID-19 during pregnancy. The study is a collaboration between Swedish and Norwegian researchers and is published in the journal JAMA.

Researchers from Karolinska Institutet have discovered that the gut microbiome can influence how well people respond to mRNA COVID vaccines. The study, published in the journal npj Biofilms and Microbiomes, suggests that certain bacteria in the gut can enhance the immune response to the vaccine, whereas other bacteria may weaken it.

Researchers at Karolinska Institutet and Danderyd Hospital have followed recipients of the new updated COVID-19 vaccine and analysed the antibody response to different SARS-CoV-2 variants. The results show a surprisingly strong response to the now dominant and highly mutated Omicron variants. [This news article has been updated]

In December, Kenneth Chien is leaving his professorship in cardiovascular research after ten years at Karolinska Institutet. He will now devote himself wholeheartedly to developing new mRNA therapies in the biotechnology industry.

The Nobel Prize in Physiology or Medicine has been awarded this year to Katalin Karikó and Drew Weissman, whose research gave rise to effective mRNA vaccines that contained the COVID pandemic and saved millions of lives. A well-deserved honour, according to Karolinska Institutet.

The Nobel Assembly at the Karolinska Institutet has today decided to award the 2023 Nobel Prize in Physiology or Medicine jointly to Katalin Karikó and Drew Weissman for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.

Vaccination protects against severe COVID-19 but not against infection. Researchers at Karolinska Institutet and Danderyd Hospital now show that protection against infection with the new omicron variants is linked to mucosal IgA antibodies, which are not induced by vaccination. These are the findings of two studies recently published in The Lancet Infectious Diseases, and The Lancet Microbe, and could explain the limited protection by currently available vaccines against infection.

A new DNA-based COVID-19 vaccine is now being tested for the first time on healthy volunteers at Karolinska University Hospital. The vaccine has been developed at Karolinska Institutet and target multiple parts of the virus, making it less vulnerable to mutated strains and potentially effective against new variants.

Vaccines against smallpox given until the mid-1970s offer continuing cross-reactive immunity to mpox (previously known as monkeypox), researchers from Karolinska Institutet report in a study published in the scientific journal Cell Host & Microbe.

Helena Hervius Askling is new in the growing group of expert coordinators at the Centre for Health Crises. Her extensive experience in the field of infectious diseases and the topic of vaccine, as a medical doctor in infectious diseases, county medical officer and associate professor, will strengthen the centre’s competence in the field.

Rumours spread faster than ever nowadays thanks to social media, and it is easy to get carried away. Some people are also inherently more vulnerable to conspiracy theories. However, sceptics’ concerns should be addressed, not dismissed, say researchers who are studying people’s willingness to take different kinds of vaccines.

High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months. Omicron infection generates durable mucosal antibodies, reducing the risk of re-infection. These are the findings of a study published in The Lancet Infectious Diseases by researchers at Karolinska Institutet and Danderyd Hospital in Sweden. The results raise further hope for the feasibility of future nasal vaccine platforms to protect against infection.

Cells that have permanently stopped multiplying, so-called senescent cells, could play an important role in the fight against cancer, according to a new study in mice by researchers at Karolinska Institutet and IRB Barcelona. The study, published in the journal Cancer Discovery, found that vaccination with senescent cancer cells significantly reduced the formation of melanoma and pancreatic cancer tumors in mice.

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine. These are the findings of a study published in The New England Journal of Medicine, led by researchers at Karolinska Institutet and Danderyd Hospital.

In a recent study researchers from Karolinska Institutet, among others, have characterised the new omicron variant BA.2.75, comparing its ability to evade antibodies against current and previous variants. The study, published in the journal The Lancet Infectious Diseases, suggests that BA.2.75 is not more resistant to antibodies than the currently dominating BA.5, which is positive news.

A new immunological treatment against hepatitis B and D viruses, both of which can cause liver cancer, shows promising results in animal models. Results from the treatment, which is being developed by researchers at Karolinska Institutet, have been published in the journal Gut.

Researchers at Karolinska Institutet are developing a coronavirus vaccine designed to be less sensitive to mutations and equipped for future strains. The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers now hope to be able to take it to safety studies on humans.

Researchers at Karolinska Institutet and Danderyd Hospital have followed participants who have received three doses of the SARS-CoV-2 vaccine and compared their immune responses after Omicron infection. The results, which are published in The Lancet Infectious Diseases, show that Omicron infection elicits significantly higher antibody responses in individuals without prior COVID-19 infection as compared to previously infected individuals.

Researchers at Karolinska Institutet have identified a new vaccine candidate against pneumococci, bacteria that can cause pneumonia, sepsis, and meningitis. The vaccine molecules comprise nano-sized membrane vesicles produced by the bacteria and provide protection in mice, a new study published in PNAS reports.

Vaccines based on inactivated SARS-CoV-2 virus are commonly used in resource-poor countries due to their low cost. New research from Karolinska Institutet shows that a booster shot of mRNA vaccine to individuals who have received two doses of inactivated vaccine offers the same level of protection against COVID-19 as three doses of mRNA vaccine. The findings are published in the journal Nature Communications.

Vaccination against COVID-19 during pregnancy is not associated with a higher risk of pregnancy complications, according to a large-scale registry study from Karolinska Institutet in Sweden and the Norwegian Institute of Public Health published in the journal JAMA.

On March 16 the Minister for International Development Cooperation visited Karolinska Institutet to discuss current research about vaccination and development cooperation for health. The visit was made in conjunction with National Vaccination Week, which has the aim of achieving more people being vaccinated against Covid 19.

The EU-funded research network Vaccelerate has now opened a European volunteer-registry of study participants for research on COVID-19 vaccines. The aim of this initiative is to boost the capacity for clinical studies on COVID-19 vaccines in the EU, but also to support vaccine research in future pandemics.

The omicron variant can partly evade the antibody response provided by vaccination or infection with previous variants of SARS-CoV-2. However, T cells still recognise omicron, scientists at Karolinska Institutet report in a study published in the journal Nature Medicine.

Media coverage of positive vaccine research can have a positive effect on overall social media sentiment – countering vaccine misinformation – but the effects wane over time. Researchers at Oxford University and Karolinska Institutet have analysed social media to investigate associations between vaccine-related major news announcements, and attitudes towards vaccines.

Antibodies in the airways quickly wane after SARS-CoV-2 infection, but vaccination results in a strong increase in antibody levels, especially after two doses, according to a new study from Karolinska Institutet published in the journal JCI Insight. The results suggest that having a second dose of vaccine also after recovering from COVID-19 may be important for protecting against re-infection and to prevent transmission.

Our bodies can fine-tune the immune response to an infection and make it proportional to the threat at hand. New research from Karolinska Institutet describes how B lymphocytes, the immune cells that make antibodies, choose between different cell fates to balance the magnitude of the acute immune response and the memory response that protects against future threats. The study, published in Immunity, may contribute to the optimisation of vaccines to fight viruses or other pathogens.

The Animal Rights Alliance (Djurrättsalliansen) is currently running a campaign to “retire” five monkeys used for research at KI. The campaign includes appeals on social media and distribution of leaflets on the Solna campus. KI uses monkeys for medical research, such as that conducted for vaccine development, when no other options are available.

Two research environments from Karolinska Institutet have been awarded grants for follow-up studies of COVID-19 vaccines. In total, six research environments from five universities will share SEK 100 million from the Swedish Research Council. The research environments are based on collaborations between different regions, and will focus on different aspects of health and medical care needs.

The human papillomavirus (HPV) can cause cancer and many countries run national vaccination programmes to minimise the risk. Studies involving researchers at German Cancer Research Center, Karolinska Institutet and Tampere University now report on the longitudinal effect of common HPV vaccines. The results, which are published in The Journal of Infectious Diseases and Lancet Infectious Diseases, show lasting protection against more HPV variants than the vaccines were developed for.

Researchers at Karolinska Institutet are investigating the efficacy and safety of COVID-19 vaccines in a new study on patients with compromised immune systems, who can become seriously ill if they are affected by COVID-19. On February 23, the first patient in the study was vaccinated with an mRNA vaccine at Karolinska University Hospital. So far, the project has received two grants from the Knut and Alice Wallenberg Foundation of SEK 10 million in total.

The European Commission has launched a contingency plan to meet the challenge of the various mutations of the coronavirus. KI and Karolinska University Hospital are contributing to a new network for the evaluation and testing of new vaccines.

For her research in HIV vaccine and design, professor Gunilla Karlsson Hedestam at the Department of Microbiology, Tumor and Cell Biology receives 1.8 million US dollar, multidisciplinary, long-term research program (P01) grant from the National Institutes of Health (NIH).

The success of the mRNA-based vaccines is a boost for the entire mRNA field and can lead to new treatments for completely different diseases. This is the view of Kenneth Chien, professor at Karolinska Institutet and co-founder of Moderna, one of the companies that has now developed a vaccine against COVID-19.

It is necessary to develop additional COVID-19 vaccines, as different vaccine approaches have their advantages and disadvantages and may work synergistically. Researchers at Karolinska Institutet in Sweden now report that they have developed a prototype vaccine against SARS-CoV-2 using a DNA vaccine platform that is inexpensive, stable, easy to produce, and shows a good safety profile. A study published in Scientific Reports shows that the vaccine induces potent immune responses in mice.

Researchers at Karolinska Institutet have led an international team of scientists who have tested a vaccine for Crimean-Congo virus on primates for the first time. The vaccine provided protection against the virus, which can cause fatal haemorrhagic fever, and showed no serious side-effects. The study is published in the journal Nature Microbiology. The next big step will be to test the vaccine on humans.

Women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age. That is according to a large study by researchers at Karolinska Institutet in Sweden published in New England Journal of Medicine.

Two recent studies were unable to rule out that H1N1 (“swine flu”) vaccination (“Pandemrix”) and seasonal influenza vaccination given to pregnant women might be associated with autism spectrum disorder in the offspring. Now, a large study by researchers at Karolinska Institutet in Sweden, published in the journal Annals of Internal Medicine, refutes any such association.

The world has essentially hit pause while waiting for a vaccine against the new coronavirus. But vaccine developer Matti Sällberg feels no pressure. “I’m a realist,” he says. “We cannot work any faster than what we already do. Others will be quicker, and therefore we are thinking long-term and focusing on finding a vaccine that can protect against several coronaviruses, including those that may pop up in the future.”

According to many observations, certain virus infections may play a part in the autoimmune attack that leads to type 1 diabetes. Researchers at Karolinska Institutet in Sweden and their Finnish colleagues have now produced a vaccine for these viruses in the hope that it could provide protection against the disease. The study is published today in the scientific journal Science Advances.

The human papillomavirus (HPV) causes, amongst other diseases, cancer of the cervix and oropharynx. A Swedish-Finnish study published in The Journal of Infectious Diseases now shows that the most oncogenic HPV types can be eliminated, but only if both girls and boys are vaccinated. Both genders will be offered vaccination in Sweden as of 2020.